Personalis Inc
personalis.comWhat Do They Do?
Sells cancer genomic tests to physicians and pharmaceutical companies, and sequencing services to diagnostic companies and population sequencing programs.
10-K for FY2025, filed Feb 26, 2026Personalis develops, markets, and sells advanced cancer genomic testing services. Our testing services are used by physicians to detect…View ↗
How Do They Make Money?
Customers pay for genomic testing services when Personalis delivers test results; invoices are typically due within 90 days.
10-K for FY2025, filed Feb 26, 2026The Company derives revenue from the sale of genomic testing services. Contracts are in the form of a combination of signed agreements…View ↗
The genomic testing services are the only distinct services that meet the definition of a performance obligation and are accounted for as…View ↗
Standard payment terms are typically 90 days or less from the invoice date, but they may vary. In instances where the timing of revenue…View ↗
$69.6M
-
10-K for FY2025, filed Feb 26, 2026
$69.6M ↗
Who Are Their Customers?
Personalis sells through a small direct sales force, while Tempus markets NeXT Personal Dx to clinical and biopharma customers. Buyers include pharmaceutical and diagnostic companies, research programs run by government, academic, and nonprofit organizations, and cancer patients.
10-K for FY2025, filed Feb 26, 2026
10-K for FY2025, filed Feb 26, 2026
We currently derive a significant portion of our revenue from Moderna by providing genomic testing in its ongoing clinical trials for its…View ↗
Do Revenues Turn Into Profits?
No. It lost $81.3M in FY2025.
10-K for FY2025, filed Feb 26, 2026
−$88.1MView ↗
10-K for FY2025, filed Feb 26, 2026
−$81.3MView ↗
10-K for FY2025, filed Feb 26, 2026
−$79.5MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
−$31.7MView ↗
- ▲ +58% (Loss)
- vs −$20.1M in Q2 FY2025
-
Aug 4, 2026
Personalis says it will no longer provide financial guidance
Sources
8-K, filed Aug 4, 2026
As a result of the announcement on July 20, 2026 that Personalis and Tempus AI, Inc. have entered into an Agreement and Plan of Merger…View ↗
-
Jul 20, 2026
Tempus agrees to acquire Personalis in a merger
Shareholders are to receive Tempus stock, with Tempus able to elect cash for up to 50% of shares.
Sources
8-K, filed Jul 20, 2026
a number of validly issued, fully paid and nonassessable shares of Parent Class A Common Stock equal to the Exchange Ratio (the “Stock…View ↗
Shrinking. Revenue fell 19% in 4 years, from $85.5M in FY2021 to $69.6M in FY2025, about 5% a year.
Clinical diagnostics
Personalis moved from preparing for expansion in clinical diagnostics to describing tests used by physicians for recurrence monitoring, treatment response, and therapy selection.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026Today, our platforms are routinely used by many of the largest oncology-focused pharmaceutical companies for analysis of patient samples in…View ↗
Personalis develops, markets, and sells advanced cancer genomic testing services. Our testing services are used by physicians to detect…View ↗
Who Do They Compete With?
Competes with Adela, Caris Life Sciences, DELFI Diagnostics, Exact Sciences, Foresight Diagnostics, Foundation Medicine, GRAIL, Guardant Health, Haystack Oncology, Laboratory Corporation of America Holdings, MedGenome, Myriad Genetics, Natera, NeoGenomics, Predicine, SAGA Diagnostics, Veracyte, Illumina, and Thermo Fisher Scientific
10-K for FY2025, filed Feb 26, 2026Our principal competition comes from commercial and academic organizations that employ various approaches to produce test results or…View ↗
Loading...
